The SARS-CoV-2 inactivated vaccine enhances the broad neutralization against variants in individuals recovered from COVID-19 up to one year

Emerg Microbes Infect. 2022 Dec;11(1):753-756. doi: 10.1080/22221751.2022.2043728.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • Neutralization Tests
  • SARS-CoV-2 / genetics
  • Spike Glycoprotein, Coronavirus / genetics
  • Vaccines, Inactivated

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Vaccines
  • SARS-CoV-2 inactivated vaccines
  • Spike Glycoprotein, Coronavirus
  • Vaccines, Inactivated
  • spike protein, SARS-CoV-2

Grants and funding

This study was supported by the National Science Fund for Distinguished Young Scholars (82025022), the National Natural Science Foundation of China (82002140, 82171752, 82101861), the Guangdong Basic and Applied Basic Research Foundation (2021B1515020034, 2019A1515011197, 2021A1515011009, 2020A1515110656), and the Shenzhen Science and Technology Program (RCYX20200714114700046, JSGG20200207155251653, JCYJ20210324131606018, JSGG20200807171401008, KQTD20200909113758004, JCYJ20190809115617365).